In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Kenvue Inc (Symbol: KVUE) has taken over the #267 spot from Biogen Inc (Symbol: BIIB), according to The Online Investor.  

	Market capitalization is an important data po

Kenvue Now #267 Largest Company, Surpassing Biogen 

Fintel reports that on October 29, 2026, Argus Research upgraded their outlook for Biogen (NASDAQGS:BIIB) (WBAG:BIIB) from Hold to Buy.Biogen Inc., based in the United States, is a prominent biotechnology firm operating in the healthcare sector, focusing on developing therapies f

Argus Research Upgrades Biogen to Buy from Hold

(RTTNews) - BioArctic AB (publ) (BIOA-B.ST) partner Eisai reported preliminary global revenue for Leqembi for the third quarter of 2026 in connection with Biogen Inc.'s (BIIB) third-quarter earnings release.

BioArctic Royalty Income Rises 74% As Leqembi Sales Reach JPY 32.2 Bln 

@media (max-width: 768px) {
                .image-container {
                    width: 100% !important;
                    float: none !important;
                    margin: 0 0 1rem 0 !important;
                }
            }
        



Image source: The Mo

Biogen (BIIB) Q3 2026 Earnings Call Transcript

Biogen Inc. reported its financial results for the third quarter ended September 30, 2026, with total revenue of $2.8 billion, representing an 11% increase year-over-year. The company's Growth Portfolio revenue reached $1.26 billion, an increase of 49% year-over-year, which inclu

Biogen Inc. Reports Third Quarter 2026 Total Revenue of $2.8 billion

(RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:30 AM ET on October 28, 2026, to discuss Q3 26 earnings results.

Biogen Q3 26 Earnings Conference Call At 8:30 AM ET 

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. News